前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的临床效果分析

Clinical Effect Analysis of Alprostadil Combined with Benazepril in the Treatment of Proteinuria in Diabetic Nephropathy

目的探析糖尿病肾病蛋白尿应用前列地尔联合贝那普利治疗的临床应用效果。方法选择该院2017年1月—2020年1月收治的102例糖尿病肾病蛋白尿患者为研究对象,按患者入院顺序与随机分组法分为对照组(n=51)与观察组(n=51),两组患者分别给予贝那普利与前列地尔联合贝那普利联合治疗。比较临床效果。结果治疗前,对照组24 h尿蛋白含量(2.58±0.59)g/d、24 h尿微白蛋白排泄率(736.42±72.35)mg/d,与观察组比较,差异无统计学意义(P>0.05);治疗后,对照组24 h尿蛋白含量(1.89±0.31)g/d、24 h尿微白蛋白排泄率(646.78±43.52)mg/d,高于观察组(t=4.523、10.232,P<0.05);治疗前,对照组SBP(161.7±9.8)mmHg、DBP(105.7±4.6)mmHg,与观察组比较,差异无统计学意义(P>0.05);治疗后,对照组SBP(140.3±9.5)mmHg、DBP(90.2±2.3)mmHg,高于观察组(t=3.545、8.231,P<0.05);治疗后,对照组好转及显效患者42(82.4%),低于观察组49(96.1%)(χ2=8.644,P<0.05)。结论糖尿病肾病蛋白尿患者应用前列地尔联合贝那普利治疗,对患者血压具有调节作用,对患者24 h尿蛋白含量、尿微白蛋白排泄量等指标具有改善作用,对患者肾脏损伤较小,具有较高安全性。

Objective To analyze the clinical application effect of alprostadil combined with benazepril in the treatment of proteinuria in diabetic nephropathy.Methods Selected 102 patients with diabetic nephropathy and proteinuria admitted to the hospital from January 2017 to January 2020 as research objects and divided them into the control group(n=51)and the observation group(n=51)according to the order of admission and randomization.Patients in the group were treated with benazepril and alprostadil combined with benazepril.Compare the clinical effects.Results Before treatment,the 24 h urine protein content of the control group(2.58±0.59)g/d and the 24 h urine microalbumin excretion rate(736.42±72.35)mg/d were the same as the observation group,the difference was not statistically significant(P>0.05).After treatment,the 24 h urine protein content of the control group was(1.89±0.31)g/d,and the 24 h urine microalbumin excretion rate(646.78±43.52)mg/d was higher than the observation group(t=4.523,10.232,P<0.05);Before treatment,the control group had SBP(161.7±9.8)mmHg and DBP(105.7±4.6)mmHg,which were no different from the observation group,,the difference was not statistically significant(P>0.05);after treatment,the control group had SBP(140.3±9.5)mmHg,DBP(90.2±2.3)mmHg,which was higher than the observation group(t=3.545,8.231,P<0.05);after treatment,42(82.4%)patients in the control group improved and markedly effective,which was lower than the observation group 49(96.1%)(χ2=8.644,P<0.05).Conclusion The application of alprostadil combined with benazepril in the treatment of proteinuria with diabetic nephropathy can regulate the blood pressure,improve the 24 h urine protein content,urine microalbumin excretion and other indicators,and cause less kidney damage,which has high security.